Efficacy of Sodium deoxyribonucleate in community-acquired pneumonia in children of school age

Cover Page

Abstract


Aim. To study efficacy of sodium deoxyribonucleate use for the treatment of community-acquired pneumonia in children of school age.

Methods. 102 children aged 7 to 17 years were observed: 25 relatively healthy children (control group), 39 children with community-acquired pneumonia, who received only conventional treatment (comparison group) and 38 patients with community-acquired pneumonia receiving complex treatment with additional sodium deoxyribonucleate (study group). All patients underwent clinical and instrumental and laboratory examination. Cytomorphologic features of neutrophils and epithelial cells, cytokine concentration (interleukin-8, -10 and -17, tumor necrosis factor α) were examined in nasal secret of patients with community-acquired pneumonia dynamically on different therapy regimens. Evaluation of dynamics of clinical signs was performed in the studied groups.

Results. In the study clinical efficacy of the medication was discovered and caused decreased disease duration, acceleration of inflammatory changes reparation in the lungs in rhinocytogram, decreased level of neutrophils and their destructive forms, decreased levels of pro-inflammatory cytokines - interleukin-8 and tumor necrosis factor α.

Conclusion. Sodium deoxyribonucleate enhances adaptive resources of mucosal immunity, leads to restoration of epithelium lining the upper respiratory airways and therefore potentiates local immunity.


O I Pikuza

Author for correspondence.
suleimanova_zulfia@mail.ru
Kazan State Medical University Kazan, Russia

R A Fayzullina

suleimanova_zulfia@mail.ru
Kazan State Medical University Kazan, Russia

Z Ya Suleymanova

suleimanova_zulfia@mail.ru
Kazan State Medical University Kazan, Russia

A M Zakirova

suleimanova_zulfia@mail.ru
Kazan State Medical University Kazan, Russia

I N Serdinskaya

suleimanova_zulfia@mail.ru
Kazan State Medical University Kazan, Russia

  • Коршунова Е.В. Особенности антибактериальной терапии внебольничных пневмоний у детей. Рос. вестн. перинатол. и педиатрии. 2008; (1): 37-43.
  • Prayle A., Atkinson M., Smyth A. Pneumonia in the developed world. Paediatr. Respir. Rev. 2011; 12 (1): 60-69. doi: 10.1016/j.prrv.2010.09.012.
  • Баранов А.А., Альбицкий В.Ю., Терлецкая Р.Н., Зелинская Д.И. Концепция сокращения предотвратимых потерь здоровья детского населения. Вопр. соврем. педиатрии. 2010; 9 (5): 5-9.
  • Каплина Э.Н., Вайнберг Ю.П. Деринат - природный иммуномодулятор для детей и взрослых. Изд. 3-е, испр. и доп. М.: Научная книга. 2017; 243 с.
  • Учайкин В.Ф. Рецидивирующие респираторные инфекции у детей: применение иммуномодуляторов для лечения и профилактики. Педиатрия. 2009; 87 (1): 127-132.
  • Ключников С.О. Часто болеющие дети. Иммунотерапия в педиатрической практике. В кн.: Лекции по педиатрии. Болезни органов дыхания. Под ред. В.Ф. Дёмина и др. М. 2011; 5: 264-267.

Views

Abstract - 9

PDF (Russian) - 5


© 2017 Pikuza O.I., Fayzullina R.A., Suleymanova Z.Y., Zakirova A.M., Serdinskaya I.N.

Creative Commons License

This work is licensed
under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.